TABLE 5.
Impact of botanical oil supplementation on cardiometabolic and inflammatory biomarkers1
| Subject genotype | ||||||
|---|---|---|---|---|---|---|
| GG | GT | TT | ||||
| Week 0 | Week 4 | Week 0 | Week 4 | Week 0 | Week 4 | |
| Triglyceride | ||||||
| SO | 70.4 (4.3) | 70.1 (6.4) | 78.1 (4.9) | 77.4 (5.4) | 94.5 (27.2) | 90.6 (16.5) |
| BO | 63.9 (3.1) | 70.5 (6.2) | 78.2 (4.5) | 85.5 (9.4) | 91.9 (15.7) | 76.4 (12.7) |
| Total cholesterol | ||||||
| SO | 167.1 (5.9) | 167.3 (8.4) | 168.5 (5.7) | 165.1 (5.5) | 165.0 (5.7) | 164.6 (6.6) |
| BO | 165.5 (7.1) | 163.3 (6.7) | 175.6 (6.2) | 173.1 (5.7) | 162.4 (3.9) | 159.8 (6.4) |
| HDL | ||||||
| SO | 65.4 (3.3) | 64.7 (3.4) | 58.3 (3.1) | 59.3 (3.0) | 57.8 (3.1) | 61.9 (4.1) |
| BO | 65.9 (3.9) | 68.0 (4.0) | 60.1 (3.1) | 64.7 (3.8) | 58.8 (5.9) | 61.5 (4.7) |
| LDL | ||||||
| SO | 86.6 (5.2) | 89.4 (6.0) | 94.5 (5.1) | 90.5 (4.6) | 88.4 (6.8) | 84.5 (6.9) |
| BO | 87.0 (6.0) | 81.0 (4.4) | 99.8 (5.7) | 91.4 (4.3) | 85.3 (7.2) | 82.9 (7.3) |
| VLDL | ||||||
| SO | 14.0 (0.80) | 14.4 (1.3) | 15.7 (1.0) | 15.4 (1.1) | 18.9 (5.5) | 18.3 (3.3) |
| BO | 12.7 (0.6) | 14.3 (1.3) | 15.7 (0.9) | 17.1 (1.9) | 18.3 (3.2) | 15.4 (2.6) |
| Glucose | ||||||
| SO | 88.4 (1.3) | 87.0 (1.2) | 89.5 (1.2) | 89.4 (1.2) | 85.5 (1.3) | 86.1 (0.7) |
| BO | 88.7 (1.3) | 87.6 (1.5) | 89.0 (1.0) | 91.2 (1.3) | 86.1 (2.0) | 89.0 (1.8) |
| hsCRP | ||||||
| SO | 0.8 (0.3) | 0.5 (0.2) | 3.8 (2.0) | 1.2 (0.3) | 0.9 (0.4) | 0.7 (0.2) |
| BO | 0.5 (0.1) | 0.6 (0.1) | 1.4 (0.3) | 1.1 (0.2) | 1.8 (1.1) | 4.6 (3.8) |
1
Values are means (SEs). Measurements of a standard lipid panel, glucose, and hsCRP were made in fasting serum at all intervention visits. Data are presented for baseline (week 0) and after week 4 of oil supplementation. The 0- and 4-wk values were not significantly different (paired t-test, by genotype) for any of the markers measured. BO, borage oil; hsCRP, high-sensitivity C-reactive protein; SO, soybean oil.